Where metabolomics
meets biology.

Cancer cells exhibit profound metabolic reprogramming — from the Warburg effect's reliance on aerobic glycolysis to flexible use of glutamine, lipids, and one-carbon metabolism. HMT's C-SCOPE, OMEGA Scan, and F-SCOPE platforms are designed to map these shifts with the precision needed to distinguish glycolytic intermediates, TCA cycle activity, and isotopomer distributions in tumour and stromal cells.

Steady-state metabolomics tells you what is present; flux analysis tells you what is moving. Using heavy-atom labelled substrates (¹³C glucose, ¹⁵N glutamine), HMT's F-SCOPE platform resolves isotopomers with the precision of CE-MS separation — enabling accurate in-vivo measurements of glucose oxidation, glutamine metabolism, and pathway activity in cells and tissues.

Metabolomics is transforming how we understand the nutritional and bioactive content of food. HMT's CE-MS and LC-MS platforms profile polar metabolites, lipid mediators, and small peptides in plant extracts, fermentation broths, and processed food matrices — linking composition to biological activity and supporting product development, quality control, and health claims.

The brain's metabolic landscape — spanning neurotransmitters, energy substrates, polyamines, and signalling molecules — is uniquely suited to CE-MS analysis. HMT's platforms are validated for brain tissue, CSF, retinal samples, and neuronal cells, enabling detailed profiling of conditions including neurodegeneration, psychiatric disease, and neuroinflammation.

Systemic infections and inflammatory diseases leave distinct metabolic signatures in plasma, serum, and urine. HMT's comprehensive profiling — combining untargeted discovery with absolute quantitation — enables identification of metabolic biomarkers associated with disease severity, treatment response, and patient stratification across bacterial, viral, and autoimmune conditions.

The skin is a metabolically active barrier organ with a distinct metabolome shaped by microbiome, exposure, and intrinsic biology. HMT profiles skin surface metabolites, biopsy extracts, and sebum samples to support research into skin ageing, microbiome-host interactions, cosmetic efficacy, and dermatological conditions.

Immune cell activation, differentiation, and effector function are tightly coupled to metabolic reprogramming. HMT's CE-MS platform captures the polar metabolite shifts — including nucleotide pools, amino acid availability, and TCA intermediates — that underpin T-cell and B-cell responses, supporting immuno-oncology, vaccine, and autoimmune research.

Microbial metabolomes are rich in compounds — organic acids, amino acids, nucleotides, secondary metabolites — that require the resolving power of CE-MS for accurate identification. HMT has validated extraction protocols for bacterial cell pellets, fungal extracts, plant roots, algae cultures, and fermentation broths across a wide range of organisms.

Taste and flavour are biochemically complex — involving small polar molecules, bitter peptides, organic acids, and lipid-derived compounds across a wide mass range. HMT's combined CE and LC platforms, including the Peptidomics option for bioactive peptides, deliver a comprehensive tastant profile to support product development, sensory science, and novel food research.

HMT's 4-point profiling platform — OMEGA Scan, Q353, LC-OMEGA, and MSCAN — generates annotated metabolite datasets of over 1,000 polar and lipid metabolites from human plasma, enabling comprehensive biomarker discovery across healthy and disease populations. The OMEGA Scan Advanced option extends this to novel, unannotated features not yet in any public database.

Mitochondrial dysfunction underlies a broad spectrum of diseases — from inherited metabolic disorders to neurodegeneration, cardiac disease, and ageing. HMT's C-SCOPE, F-SCOPE, and OMEGA Scan platforms quantify TCA cycle intermediates, respiratory chain metabolites, and energy cofactors with the precision required to characterise mitochondrial pathway activity.

Metabolomic patient profiling enables stratification of heterogeneous disease populations into biochemically distinct subgroups — revealing differences in drug response, disease progression, and clinical outcome that are invisible to genomics alone. HMT's comprehensive plasma profiling provides over 1,000 annotated metabolites per sample for cohort-scale studies.

Engineering productive cell lines — whether for recombinant protein production, CAR-T therapy, or cultivated meat — requires real-time insight into cellular metabolism. HMT's CE-MS platform maximises polar metabolite coverage of growth media and cell extracts, while LC-MS adds lipid and fatty acid profiling, enabling optimisation of culture conditions and product yields.

Metabolomics is becoming an essential tool in biomanufacturing — from fermentation monitoring and media optimisation to quality control and process analytical technology (PAT). HMT's platforms support the metabolic characterisation of microbial, yeast, and mammalian production systems at any scale, from early development to GMP-adjacent clinical manufacturing.